Bispecifics in the CAR-T era: where do they fit?

(1:26)

The potential role of bispecifics in Hodgkin lymphoma

(1:50)

The current and future role of bispecifics in R/R DLBCL: epcoritamab, glofitamab \u0026 more

(2:8)

What Are Bispecifics in Multiple Myeloma? (For Patients and Caregivers) | Dr. Joshua Richter

(5:20)

An insight into the sequencing of CAR-T and bispecifics in myeloma

(2:7)

An overview of bispecifics in R/R myeloma and their integration into the treatment landscape

(4:2)

The growing importance of bispecific antibodies in the treatment of multiple myeloma

(1:47)

Bispecifics in NHL: epcoritamab and glofitamab

(1:26)

CRS Management, Considerations for Bispecifics in Multiple Myeloma

(8:7)

Bispecifics Part I: Immune System and Immunotherapy Basics

(3:8)

The promise of elranatamab and other bispecifics in the treatment of myeloma

(1:37)

Meera Mohan, MD, on Infectious Complications with Bispecifics in Multiple Myeloma

(7:25)

Feasibility of treatment with bispecifics in patients with myeloma with prior BCMA exposure

(1:6)

How Bispecific Antibodies Work

(25)

The future of CAR-T and bispecifics in myeloma: successful integration into earlier lines

(1:42)

A look into the future: CAR-T and bispecifics in myeloma

(3:38)

Comparison of the safety \u0026 efficacy of CAR-T therapy vs bispecifics in R/R multiple myeloma

(6:38)

T-cell bispecifics in AML: ongoing challenges and future outlooks

(2:22)

The value of bispecifics in myeloma \u0026 the importance of optimally sequencing immunotherapies

(1:27)